March 22nd 2023
Patients with metastatic or recurrent locally advanced Merkel cell carcinoma can now receive treatment with retifanlimab-dlwr following its accelerated approval by the FDA.
Secondary Prevention Strategies for Nonmelanoma Skin CancerApril 15th 2018
In this article, we review the published literature and evaluate secondary prevention strategies for nonmelanoma skin cancer. We also explore investigational therapies proposed for chemoprevention of nonmelanoma skin cancers.
Novel, Immune Therapies Promising in Nonmelanoma Skin CancersMarch 9th 2017
Treatment of keratinocyte carcinomas such as basal cell carcinoma and cutaneous squamous cell carcinoma with PD-1 checkpoint inhibitors and targeted agents warrant further investigation, according to recently published studies.
Chemical Compound May Help Reduce the Spread of MelanomaJanuary 17th 2017
There is a lot of interest in a new treatment that kills approximately 90% of melanoma cancer cells, an astounding accomplishment for Richard Neubig, MD, PhD, who serves as chairperson of pharmacology toxicology at Michigan State University.
Viral Oncoprotien Antibodies May Help Detect Merkel Cell Carcinoma RecurrenceDecember 13th 2016
Scientists have found a way to detect earlier if Merkel cell carcinoma (MCC) is recurring in patients. They have published a paper in the journal Cancer demonstrating how an immune system marker may be able to outperform and supplement imaging studies for recurrence of MCC.
Predicting Patient Outcomes With Mathematical Modeling in Virtual Clinical TrialsNovember 22nd 2016
Researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Department are overcoming some of the limitations of common preclinical experiments and clinical trials by studying cancer through mathematical modeling.
Immune, Targeted Therapies Plus Radiation Ups Survival in Melanoma Patients With Brain MetastasesSeptember 30th 2016
Researchers at Moffitt Cancer Center in Tampa, Fla., demonstrated how novel immune and targeted therapies with radiation therapy may improve the outcomes of patients with melanoma who have brain metastases.
Encorafenib and Binimetinib Combo May Help Improve Survival in Patients With BRAF-Mutant MelanomaSeptember 28th 2016
Combining the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib may significantly improve progression-free survival in BRAF mutant melanoma, according to a new phase III trial.
Impediments to Skin Cancer Prevention Among Minorities, UninsuredSeptember 16th 2016
Lack of knowledge and a belief that dark skin protects against skin cancer are among the barriers preventing minority, uninsured, and immigrant populations from adopting methods for skin cancer prevention.
Eye Color Genes Linked to Uveal Melanoma RiskSeptember 1st 2016
Scientists from the Ohio State University (The James) Comprehensive Cancer Center and Perlmutter Cancer Center of NYU School of Medicine have found an association between genes linked to eye color and development of uveal melanoma.